SCHEMBL4150274

SCHEMBL4150274

NC(c1cccc(Cl)c1)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 5/20 0.52
ROCK1 Q13464 2/20 0.52
GAA P10253 1/20 0.42
CYP1A2 P05177 1/20 0.39
CYP19A1 P11511 1/20 0.37
KDM4E B2RXH2 2/20 0.36
RAB9A P51151 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
BACE1 P56817 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
COASY Q13057 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
CYP3A4 P08684 1/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
TACR1 P25103 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL586819 0.90 GAA (0.46) ROCK2ROCK1GAACYP1A2CYP19A1
SCHEMBL4826538 0.90 GAA (0.46) ROCK2ROCK1GAACYP1A2CYP19A1
SCHEMBL5097077 0.87 ROCK2 (0.49) ROCK2ROCK1GAACYP1A2KDM4E
SCHEMBL586656 0.84 CYP19A1 (0.46) ROCK2ROCK1GAACYP1A2CYP19A1
SCHEMBL4149043 0.80 GAA (0.42) ROCK2ROCK1GAACYP1A2CYP19A1
SCHEMBL5103630 0.80 ROCK2 (0.37) ROCK2ROCK1GAACYP1A2KDM4E
SCHEMBL5100663 0.78 ALDH1A1 (0.54) ROCK2ROCK1GAACYP1A2KDM4E
SCHEMBL1479636 0.77 LMNA (0.42) GAACYP1A2KDM4EHTR3EHTR3B
SCHEMBL580393 0.77 LMNA (0.42) GAACYP1A2KDM4EHTR3EHTR3B
SCHEMBL5104456 0.77 LMNA (0.42) GAACYP1A2KDM4EHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-07-16 US disclosed
US-7429597-B2 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-09-30 US disclosed
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-06-05 US disclosed
US-7326791-B2 Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) 2008-02-05 US disclosed
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 ROCK2 2940/4885ROCK1 1960/4885GAA 370/4885
US-20040176603-A1 Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions F11, F12, F2 ROCK2 3184/4885ROCK1 989/4885GAA 2024/4885
US-20090181958-A1 SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 ROCK2 3223/4885ROCK1 1920/4885GAA 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.